Olopatadine

Introduction Overview

Generic Name

Olopatadine

Brand Name

Pataday, Patanase, Patanol

Dosage Form

Ophthalmic Solution, Nasal Spray

Drug Class

Antiallergic Agents; Histamine H1-receptor Antagonists; Mast-cell Stabilizers

Pharmacokinetics

Absorption:
Olopatadine exhibits differential absorption profiles depending on its route of administration. When applied topically in ophthalmic solutions, systemic absorption is minimal with plasma concentrations typically undetectable, leading to limited systemic exposure. Conversely, intranasally administered olopatadine shows a higher systemic bioavailability with an average absolute bioavailability of approximately 57% in healthy individuals. Peak plasma concentrations after nasal spray administration are typically reached between 15 minutes and 2 hours, highlighting its rapid absorption through the nasal mucosa. Notably, onset of action for ocular administration is rapid, often providing symptomatic relief within 30 minutes, while nasal spray efficacy is observed after approximately one day of use. These pharmacokinetic properties underscore the rapid therapeutic effect sought in allergy symptom relief.

Distribution:
Detailed characterization of olopatadine distribution into ocular tissues and fluids remains limited. However, systemic distribution indicates moderate plasma protein binding, approximately 55%, primarily to albumin, which influences its pharmacodynamics and potential drug interactions. The distribution supports effective concentrations at the site of action within ocular and nasal tissues while maintaining low systemic levels to reduce systemic adverse effects.

Metabolism:
Olopatadine is not extensively metabolized following systemic absorption. After oral administration, the unchanged parent compound constitutes approximately 77% of plasma total radioactivity, with less than 6% represented by metabolites such as olopatadine N-oxide and N-desmethyl olopatadine. The minimal metabolism suggests reduced potential for metabolic drug interactions and a predictable pharmacokinetic profile.

Elimination:
Elimination occurs predominantly through renal excretion, with 60–70% of systemically absorbed olopatadine eliminated in the urine, and 86% of this excreted as unchanged drug. Fecal elimination accounts for about 17%. The elimination half-life varies by administration route, approximately 3 hours after topical ocular application and 8–12 hours following oral administration, indicating a sustained presence suitable for twice-daily dosing regimens. Renal impairment does not markedly affect peak plasma concentrations following nasal dosing, implying no dosage adjustment is necessary in mild to severe renal dysfunction. This renal elimination pathway highlights the importance of renal function assessment in patient populations.

Dosage Forms

Available Dosage Forms:
Olopatadine is commercially available in two primary dosage forms, tailored for ophthalmic and intranasal administration to address allergic conjunctivitis and seasonal allergic rhinitis, respectively.

Ophthalmic Solution:
- 0.1% (1 mg/mL) solution (Brand: Patanol, Alcon)
- 0.2% (2 mg/mL) solution (Brand: Pataday, Alcon)

Nasal Spray:
- 0.6% olopatadine hydrochloride solution, delivering 600 mcg per metered spray (Brand: Patanase, Alcon)
Approximately 240 metered sprays per 30.5 g bottle.

Dosages for Adults and Adolescents:
Ophthalmic Application:
- 0.1% solution: 1 drop in affected eye(s) twice daily at 6–8 hour intervals.
- 0.2% solution: 1 drop in affected eye(s) once daily.
- Administer different topical ophthalmic drugs at least 5 minutes apart to prevent dilution or interaction.

Nasal Spray Application:
- Adults (≥12 years): 2 sprays (1200 mcg) in each nostril twice daily.
- Adolescents (12–17 years): same dosing as adults.

Dosages for Pediatric Patients:
Ophthalmic Application:
- Children ≥3 years: 0.1% solution, 1 drop twice daily (6–8 hour intervals).
- Children ≥2 years: 0.2% solution, 1 drop once daily.

Nasal Spray Application:
- Children 6–11 years: 1 spray (600 mcg) in each nostril twice daily.
- Safety and efficacy not established in children under 6 years for nasal spray; under 3 years for 0.1% ophthalmic; under 2 years for 0.2% ophthalmic.

Specific Patient Populations:
- Hepatic Impairment: No dosage adjustment required for nasal spray.
- Renal Impairment: No dosage adjustment recommended; peak plasma levels are not significantly altered.
- Geriatric Use: Dosage should be selected with caution due to potential decreased hepatic, renal, or cardiac function; however, safety profile is comparable to younger adults for ophthalmic use.

Administration Instructions:
Nasal spray must be primed before initial use and if unused for more than 7 days. Proper techniques including alternating nostrils and avoiding spraying into the eyes are essential to minimize adverse effects. Ophthalmic drops require avoiding lens placement during administration and adherence to hygiene to prevent contamination.

Mechanism Of Action

Olopatadine functions primarily as a selective histamine H1-receptor antagonist and a mast cell stabilizer, making it a dual-action antiallergic agent. By selectively binding to H1 receptors on vascular and other target tissues, olopatadine inhibits the action of histamine, a key mediator in allergic responses responsible for pruritus, vasodilation, increased vascular permeability, and conjunctival redness.

Concurrently, olopatadine stabilizes mast cells, preventing degranulation and the subsequent release of inflammatory mediators including histamine, prostaglandin D2, tryptase, and leukotrienes. This dual inhibitory effect not only mitigates immediate hypersensitivity reactions but also reduces the recruitment and activation of eosinophils, which contribute to sustained inflammatory responses characteristic of allergic conjunctivitis and rhinitis.

At the cellular level, olopatadine reduces histamine-stimulated conjunctival vascular permeability in a concentration-dependent manner and decreases chemotaxis of inflammatory cells. This attenuates the cascade of inflammatory signaling pathways and disrupts the propagation of allergic inflammation in ocular and nasal tissues. Compared to other ocular antihistamines such as levocabastine, olopatadine demonstrates comparable potency, with superior inhibition relative to pheniramine and antazoline.

Clinical implications of the mechanism include rapid symptom relief and prolonged duration of action, with effects sustained for 8 hours or more in ocular use and effective nasal symptom control following twice-daily dosing. This pharmacological profile enables olopatadine to effectively control both immediate and late-phase allergic reactions, improving patient quality of life during allergy seasons and minimizing the need for concomitant therapies.

Pharmacological Actions

Selective antagonist of histamine H1 receptors to prevent histamine-mediated allergic symptoms.
Mast cell stabilizer that inhibits antigen-induced degranulation, reducing release of histamine and other inflammatory mediators.
Suppresses production and release of prostaglandin D2 and tryptase, further attenuating allergic inflammation.
Decreases chemotaxis and activation of eosinophils involved in late-phase allergic responses.
Inhibits histamine-stimulated conjunctival vascular permeability in a dose-dependent manner to reduce ocular redness and edema.
Exhibits rapid onset of action with symptomatic relief of itching within 30 minutes in ophthalmic use.
Provides long duration of action (≥8 hours) facilitating convenient dosing schedules.
Administered via ophthalmic and intranasal routes to target localized allergic symptoms effectively.
Does not exhibit significant systemic antagonism of other histamine receptor subtypes, reducing off-target effects.
Demonstrates potency comparable to levocabastine and exceeds that of pheniramine or antazoline in ocular allergy management.
Minimal systemic absorption reduces systemic adverse effects and drug interactions.
Blocks type I immediate hypersensitivity reactions in vitro and in vivo models.
Reduces nasal congestion, rhinorrhea, sneezing, and nasal itching through nasal mucosa histamine blockade.
Maintains safety and efficacy in pediatric and adult populations with appropriate dosing adjustments.
No significant inhibition or induction of CYP isoenzymes, minimizing metabolic drug interaction potential.

Therapeutic Or Clinical Uses

Management of symptomatic ocular itching associated with allergic conjunctivitis.
Treatment of seasonal allergic conjunctivitis in adults and children.
Relief of nasal symptoms related to seasonal allergic rhinitis including nasal congestion, rhinorrhea, nasal itching, and sneezing.
Symptomatic treatment of hay fever (seasonal allergic rhinitis).
Used as an alternative to oral antihistamines to reduce systemic side effects in allergic eye and nasal conditions.
Adjunctive therapy for patients experiencing allergic symptoms refractory to conventional mast cell stabilizers.
Provides rapid onset and sustained relief improving patient compliance and quality of life during allergy seasons.
Off-label use may include management of other immediate hypersensitivity ocular or nasal disorders where histamine plays a pathogenic role.
Use in patients intolerant to corticosteroids or requiring steroid-sparing allergic symptom control.
Topical ophthalmic form not recommended for contact lens-related ocular irritation, emphasizing its specificity for allergic conjunctivitis.
Nasal spray used as first-line in intranasal pharmacotherapy for allergic rhinitis for rapid symptom alleviation.
Effective in both adult and pediatric populations with age-appropriate dosing recommendations.
Safe for use in patients with mild to moderate hepatic or renal impairment without dosage adjustment.
Considered a Category C drug in pregnancy; use only if benefits justify potential risk.
Well tolerated with low incidence of systemic adverse events, allowing chronic use during allergen exposure periods.

Side Or Adverse Effects

Headache is the most commonly reported adverse effect with ophthalmic 0.1% formulation.
Symptoms resembling cold syndrome, including pharyngitis, reported with 0.2% ophthalmic solution.
Bitter taste reported following nasal spray administration, which may reduce patient adherence.
Epistaxis (nosebleed), nasal ulcerations, and nasal septal perforation have been reported with nasal spray use.
Somnolence and CNS depression noted particularly with nasal spray; caution advised when engaging in alertness-required activities.
Pharyngolaryngeal pain, postnasal drip, and cough observed with nasal administration.
Upper respiratory tract infections, rash, and pyrexia reported in pediatric nasal spray users.
Contact lens intolerance due to preservatives in ophthalmic solution; soft lenses should be removed prior to dosing.
Local ocular irritation such as burning, stinging, or dryness may occur after topical application.
Rare hypersensitivity reactions including allergic conjunctivitis exacerbations or ocular edema.
Urinary tract infections documented in some nasal spray users during clinical trials.
Potential for bitter or unpleasant taste if nasal spray is incorrectly administered (e.g., spraying into the mouth).
Transient ocular discomfort and foreign body sensation reported post-ophthalmic instillation.
Occasional reports of drowsiness, which may be additive with concomitant CNS depressants.
No significant systemic adverse effects expected due to minimal systemic absorption.

Precautions

Avoid contamination of ophthalmic solution by not touching the dropper tip to eyes, eyelids, or surrounding areas.
Remove soft contact lenses before ophthalmic administration; wait at least 10 minutes before reinsertion, unless eyes are red.
Do not wear contact lenses if ocular redness is present, as olopatadine is not indicated for contact lens-related irritation.
Prime nasal spray pump before first use and if unused for more than 7 days to ensure accurate dosing.
Perform nasal examination prior to initiating nasal spray therapy to rule out existing nasal diseases.
Monitor periodically for nasal mucosal adverse effects such as ulcerations during nasal spray therapy; discontinue if present.
Avoid spraying nasal formulation into eyes to prevent irritation and unpleasant taste.
Patients using nasal spray should be cautioned about the potential for somnolence and advised against driving or operating machinery until response to the drug is known.
Avoid concomitant use of nasal spray with alcohol or other CNS depressants due to additive CNS depression risk.
Use caution in geriatric patients due to possible age-related organ function decline and potential concomitant illnesses.
Use during pregnancy only if potential benefit justifies the risk; classified as Category C.
Use caution during lactation; limited data on human breast milk excretion exist; weigh benefits against risks.
In pediatric patients, adhere to age-specific dosing due to differences in safety and efficacy in younger children.
Inform patients to report any signs of hypersensitivity or severe adverse reactions promptly.
Ensure proper patient education on administration techniques to maximize therapeutic benefits and minimize adverse events.

Warnings

Known hypersensitivity to olopatadine or any ingredient in the ophthalmic formulation contraindicates use of the eye drops.
No known contraindications for nasal spray; however, caution advised with existing nasal mucosal disease.
Risk of nasal ulcerations and epistaxis warrants close monitoring and discontinuation upon mucosal damage detection.
Potential for somnolence may impair mental alertness; patients should avoid hazardous activities post nasal spray use.
Avoid contamination of ophthalmic solution to prevent secondary infections.
Not indicated for treatment of contact lens-induced eye irritation; inappropriate use may exacerbate symptoms.
Pregnancy Category C; use only if benefits outweigh potential fetal risks.
Use in pediatric patients younger than recommended age is not advised due to lack of safety and efficacy data.
Patients with severe hepatic or renal impairment require cautious use despite no formal dose adjustment recommendations.
Concomitant CNS depressant use with olopatadine nasal spray may potentiate sedation.
Potential for bitter taste and local irritation leading to discontinuation; patients should be counseled accordingly.
Discard nasal spray after 240 sprays to avoid dosing inaccuracies and microbial contamination.
Improper storage or handling may reduce drug effectiveness and increase infection risk.
Patients should not blow their nose or tilt their head backward immediately after nasal spray administration to minimize adverse taste.
Use with caution in elderly patients due to possible decreased drug clearance and polypharmacy.

Contraindication

Known hypersensitivity or allergic reaction to olopatadine or any component of the ophthalmic preparation.
Not indicated and contraindicated for contact lens-related ocular irritation or infections.
Avoid nasal spray in patients with existing nasal ulcerations or severe nasal septal perforations until resolution.
Contraindicated in patients with a known history of hypersensitivity reactions such as anaphylaxis to this drug.
Failure to adhere to administration instructions (e.g., spraying into eyes or ingestion) contraindicates use until corrected.
Use contraindicated in cases where contamination of ophthalmic drops has occurred to prevent eye infections.
Contraindicated in pediatric patients younger than approved age limits due to safety data absence.
Use contraindicated in patients with severe ocular infections or inflammations requiring corticosteroids or antibiotics.
Concurrent use with other intranasal medications without medical supervision is contraindicated.
Additional contraindications may exist based on excipients in specific formulations; review of product labeling is necessary.

Drug Interactions

No formal drug interaction studies have been conducted with olopatadine ophthalmic solution or nasal spray.
Olopatadine does not significantly inhibit cytochrome P450 enzymes (CYP1A2, 2C9, 2C19, 2D6, 2E1, 3A4), minimizing metabolic drug interactions.
Eliminated primarily via renal excretion; interactions with drugs affecting hepatic enzymes are unlikely.
Modest plasma protein binding (~55%) reduces risk of displacement interactions with other protein-bound drugs.
Caution advised when nasal spray is used concomitantly with CNS depressants such as alcohol or sedative medications due to potential additive CNS depression.
No known interactions with common ophthalmic medications; however, administer different ophthalmic agents at least 5 minutes apart to avoid dilution or washout.
Potential interactions with other intranasal agents have not been fully evaluated; medical supervision recommended.
No documented interaction with antihistamines or corticosteroids administered systemically or locally.
No reported interactions affecting the pharmacodynamic efficacy of olopatadine.
No significant interaction with commonly prescribed cardiovascular, metabolic, or antimicrobial agents.
Use caution in patients taking medications causing CNS depression when administering nasal spray formulation.
Clinical vigilance is warranted when olopatadine is added to complex therapeutic regimens due to limited interaction data.
No evidence to suggest olopatadine alters the pharmacokinetics of concurrently administered drugs.
No data suggest interference with laboratory tests or diagnostic procedures.
Patients should be advised to inform healthcare providers of all concurrent medications, including OTC products.

Preparations Of The Drug

Olopatadine Hydrochloride Nasal Spray, 0.6% solution delivering 600 mcg per metered dose (Brand: Patanase, Alcon).
Olopatadine ophthalmic solution 0.1% (w/v) for topical ocular use (Brand: Patanol, Alcon).
Olopatadine ophthalmic solution 0.2% (w/v) for topical ocular use (Brand: Pataday, Alcon).
Formulations contain preservatives such as benzalkonium chloride in ophthalmic solutions, requiring contact lens considerations.
Nasal spray formulations are supplied in metered-dose pump bottles designed for precise intranasal administration with priming instructions.
Packaging includes tamper-evident caps and instruction leaflets detailing proper usage.
Stored at recommended temperatures: nasal spray at 4–25°C; ophthalmic solution at 2–25°C.
Commercially available in multidose containers with defined expiration after opening (e.g., nasal spray discarded after 240 sprays).
Available through prescription; some formulations may have generic equivalents depending on region.
Compositions are subject to regulatory and manufacturer-specific excipients, consulting labels for allergies is recommended.
Delivered via topical and intranasal routes only; no oral or injectable formulations available.
Packaging designed to minimize contamination risk with instructions for proper hygiene included.
Formulations are indicated for once or twice daily administration according to concentration and indication.
Certain preparations have pediatric dosing guidelines incorporated in the prescribing information.
Preparations are available through multiple manufacturers with Alcon identified as a primary supplier for brand products.